Pharmacogenetics and pharmacogenomics in rheumatology

Zoltán Szekanecz; Bertalan Meskó; Szilard Poliska; Andrea Váncsa; Szilvia Szamosi; Edit Végh; Enikö Simkovics; Judit Laki; Júlia Kurkó; Timea Besenyei; Katalin Mikecz; Tibor T. Glant; László Nagy

doi:10.1007/s12026-013-8405-z

Pharmacogenetics and pharmacogenomics in rheumatology

Zoltán Szekanecz, Bertalan Meskó, Szilard Poliska, Andrea Váncsa, Szilvia Szamosi, Edit Végh, Enikö Simkovics, Judit Laki, Júlia Kurkó, Timea Besenyei, Katalin Mikecz, Tibor T. Glant, László Nagy

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Pharmacogenetics and pharmacogenomics deal with possible associations of a single genetic polymorphism or those of multiple gene profiles with responses to drugs. In rheumatology, genes and gene signatures may be associated with altered efficacy and/or safety of anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs) and biologics. In brief, genes of cytochrome P450, other enzymes involved in drug metabolism, transporters and some cytokines have been associated with responses to and toxicity of non-steroidal anti-inflammatory drugs, corticosteroids and DMARDs. The efficacy of biologics may be related to alterations in cytokine, chemokine and FcγR genes. Numerous studies reported multiple genetic signatures in association with responses to biologics; however, data are inconclusive. More, focused studies carried out in larger patient cohorts, using pre-selected genes, may be needed in order to determine the future of pharmacogenetics and pharmacogenomics as tools for personalized medicine in rheumatology.

Original language	English (US)
Pages (from-to)	325-333
Number of pages	9
Journal	Immunologic Research
Volume	56
Issue number	2-3
DOIs	https://doi.org/10.1007/s12026-013-8405-z
State	Published - Jul 2013
Externally published	Yes

Keywords

Biologics
DMARDs
Genetic signature
NSAIDs
Pharmacogenetics
Pharmacogenomics
Rheumatoid arthritis
SNP

ASJC Scopus subject areas

Immunology

Access to Document

10.1007/s12026-013-8405-z

Cite this

@article{c8a438e838ee4ee8b7ff685302bf67ec,

title = "Pharmacogenetics and pharmacogenomics in rheumatology",

abstract = "Pharmacogenetics and pharmacogenomics deal with possible associations of a single genetic polymorphism or those of multiple gene profiles with responses to drugs. In rheumatology, genes and gene signatures may be associated with altered efficacy and/or safety of anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs) and biologics. In brief, genes of cytochrome P450, other enzymes involved in drug metabolism, transporters and some cytokines have been associated with responses to and toxicity of non-steroidal anti-inflammatory drugs, corticosteroids and DMARDs. The efficacy of biologics may be related to alterations in cytokine, chemokine and FcγR genes. Numerous studies reported multiple genetic signatures in association with responses to biologics; however, data are inconclusive. More, focused studies carried out in larger patient cohorts, using pre-selected genes, may be needed in order to determine the future of pharmacogenetics and pharmacogenomics as tools for personalized medicine in rheumatology.",

keywords = "Biologics, DMARDs, Genetic signature, NSAIDs, Pharmacogenetics, Pharmacogenomics, Rheumatoid arthritis, SNP",

author = "Zolt{\'a}n Szekanecz and Bertalan Mesk{\'o} and Szilard Poliska and Andrea V{\'a}ncsa and Szilvia Szamosi and Edit V{\'e}gh and Enik{\"o} Simkovics and Judit Laki and J{\'u}lia Kurk{\'o} and Timea Besenyei and Katalin Mikecz and Glant, {Tibor T.} and L{\'a}szl{\'o} Nagy",

note = "Funding Information: Acknowledgments This work was supported by research grants ETT 315/2009 from the Medical Research Council of Hungary (Z.S.); OTKA K 105073 from the National Scientific Research Fund of Hungary (Z.S.), Grants WS1695414 and WS1695450 by Pfizer (Z.S.), Grant AR059356 (T.T.G.), and by the T{\'A}MOP 4.2.1/B-09/1/KONV-2010-0007 and 4.2.2.A-1/11/KONV-2012-0031 projects co-financed by the European Union and the European Social Fund (Z.S.).",

year = "2013",

month = jul,

doi = "10.1007/s12026-013-8405-z",

language = "English (US)",

volume = "56",

pages = "325--333",

journal = "Immunologic Research",

issn = "0257-277X",

publisher = "Humana Press",

number = "2-3",

}

TY - JOUR

T1 - Pharmacogenetics and pharmacogenomics in rheumatology

AU - Szekanecz, Zoltán

AU - Meskó, Bertalan

AU - Poliska, Szilard

AU - Váncsa, Andrea

AU - Szamosi, Szilvia

AU - Végh, Edit

AU - Simkovics, Enikö

AU - Laki, Judit

AU - Kurkó, Júlia

AU - Besenyei, Timea

AU - Mikecz, Katalin

AU - Glant, Tibor T.

AU - Nagy, László

N1 - Funding Information: Acknowledgments This work was supported by research grants ETT 315/2009 from the Medical Research Council of Hungary (Z.S.); OTKA K 105073 from the National Scientific Research Fund of Hungary (Z.S.), Grants WS1695414 and WS1695450 by Pfizer (Z.S.), Grant AR059356 (T.T.G.), and by the TÁMOP 4.2.1/B-09/1/KONV-2010-0007 and 4.2.2.A-1/11/KONV-2012-0031 projects co-financed by the European Union and the European Social Fund (Z.S.).

PY - 2013/7

Y1 - 2013/7

N2 - Pharmacogenetics and pharmacogenomics deal with possible associations of a single genetic polymorphism or those of multiple gene profiles with responses to drugs. In rheumatology, genes and gene signatures may be associated with altered efficacy and/or safety of anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs) and biologics. In brief, genes of cytochrome P450, other enzymes involved in drug metabolism, transporters and some cytokines have been associated with responses to and toxicity of non-steroidal anti-inflammatory drugs, corticosteroids and DMARDs. The efficacy of biologics may be related to alterations in cytokine, chemokine and FcγR genes. Numerous studies reported multiple genetic signatures in association with responses to biologics; however, data are inconclusive. More, focused studies carried out in larger patient cohorts, using pre-selected genes, may be needed in order to determine the future of pharmacogenetics and pharmacogenomics as tools for personalized medicine in rheumatology.

AB - Pharmacogenetics and pharmacogenomics deal with possible associations of a single genetic polymorphism or those of multiple gene profiles with responses to drugs. In rheumatology, genes and gene signatures may be associated with altered efficacy and/or safety of anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs) and biologics. In brief, genes of cytochrome P450, other enzymes involved in drug metabolism, transporters and some cytokines have been associated with responses to and toxicity of non-steroidal anti-inflammatory drugs, corticosteroids and DMARDs. The efficacy of biologics may be related to alterations in cytokine, chemokine and FcγR genes. Numerous studies reported multiple genetic signatures in association with responses to biologics; however, data are inconclusive. More, focused studies carried out in larger patient cohorts, using pre-selected genes, may be needed in order to determine the future of pharmacogenetics and pharmacogenomics as tools for personalized medicine in rheumatology.

KW - Biologics

KW - DMARDs

KW - Genetic signature

KW - NSAIDs

KW - Pharmacogenetics

KW - Pharmacogenomics

KW - Rheumatoid arthritis

KW - SNP

UR - http://www.scopus.com/inward/record.url?scp=84879551758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879551758&partnerID=8YFLogxK

U2 - 10.1007/s12026-013-8405-z

DO - 10.1007/s12026-013-8405-z

M3 - Article

C2 - 23564183

AN - SCOPUS:84879551758

SN - 0257-277X

VL - 56

SP - 325

EP - 333

JO - Immunologic Research

JF - Immunologic Research

IS - 2-3

ER -

Pharmacogenetics and pharmacogenomics in rheumatology

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this